Co-Authors
This is a "connection" page, showing publications co-authored by Ulrich Strych and Peter Hotez.
Connection Strength
1.506
-
COVID-19 vaccines: neutralizing antibodies and the alum advantage. Nat Rev Immunol. 2020 07; 20(7):399-400.
Score: 0.223
-
Engineering a stable CHO cell line for the expression of a MERS-coronavirus vaccine antigen. Vaccine. 2018 03 27; 36(14):1853-1862.
Score: 0.189
-
Optimization of the Production Process and Characterization of the Yeast-Expressed SARS-CoV Recombinant Receptor-Binding Domain (RBD219-N1), a SARS Vaccine Candidate. J Pharm Sci. 2017 08; 106(8):1961-1970.
Score: 0.178
-
Lives and Costs Saved by Expanding and Expediting Coronavirus Disease 2019 Vaccination. J Infect Dis. 2021 09 17; 224(6):938-948.
Score: 0.061
-
A yeast expressed RBD-based SARS-CoV-2 vaccine formulated with 3M-052-alum adjuvant promotes protective efficacy in non-human primates. Sci Immunol. 2021 07 15; 6(61).
Score: 0.060
-
Process development and scale-up optimization of the SARS-CoV-2 receptor binding domain-based vaccine candidate, RBD219-N1C1. Appl Microbiol Biotechnol. 2021 May; 105(10):4153-4165.
Score: 0.059
-
SARS-CoV-2 RBD219-N1C1: A yeast-expressed SARS-CoV-2 recombinant receptor-binding domain candidate vaccine stimulates virus neutralizing antibodies and T-cell immunity in mice. Hum Vaccin Immunother. 2021 08 03; 17(8):2356-2366.
Score: 0.059
-
Genetic modification to design a stable yeast-expressed recombinant SARS-CoV-2 receptor binding domain as a COVID-19 vaccine candidate. Biochim Biophys Acta Gen Subj. 2021 06; 1865(6):129893.
Score: 0.058
-
The Benefits of Vaccinating With the First Available COVID-19 Coronavirus Vaccine. Am J Prev Med. 2021 05; 60(5):605-613.
Score: 0.058
-
Correlates and disparities of intention to vaccinate against COVID-19. Soc Sci Med. 2021 03; 272:113638.
Score: 0.058
-
Yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with aluminum hydroxide induces protective immunity and reduces immune enhancement. Vaccine. 2020 11 03; 38(47):7533-7541.
Score: 0.057
-
Vaccine Efficacy Needed for a COVID-19 Coronavirus Vaccine to Prevent or Stop an Epidemic as the Sole Intervention. Am J Prev Med. 2020 10; 59(4):493-503.
Score: 0.056
-
Coronavirus vaccine-associated lung immunopathology-what is the significance? Microbes Infect. 2020 10; 22(9):403-404.
Score: 0.056
-
The SARS-CoV-2 Vaccine Pipeline: an Overview. Curr Trop Med Rep. 2020 Mar 03; 1-4.
Score: 0.054
-
Economic value of a therapeutic Chagas vaccine for indeterminate and Chagasic cardiomyopathy patients. Vaccine. 2019 06 19; 37(28):3704-3714.
Score: 0.051
-
Covalent vaccination with Trypanosoma cruzi Tc24 induces catalytic antibody production. Parasite Immunol. 2018 Nov; 40(11):e12585.
Score: 0.049
-
Characterization and Stability of Trypanosoma cruzi 24-C4 (Tc24-C4), a Candidate Antigen for a Therapeutic Vaccine Against Chagas Disease. J Pharm Sci. 2018 05; 107(5):1468-1473.
Score: 0.047
-
Yeast-expressed recombinant As16 protects mice against Ascaris suum infection through induction of a Th2-skewed immune response. PLoS Negl Trop Dis. 2017 Jul; 11(7):e0005769.
Score: 0.045
-
Mutations to Cysteine Residues in the Trypanosoma cruzi B-Cell Superantigen Tc24 Diminish Susceptibility to IgM-Mediated Hydrolysis. J Parasitol. 2017 10; 103(5):579-583.
Score: 0.045
-
A simple fluorescence-based assay for quantification of the Toll-Like Receptor agonist E6020 in vaccine formulations. Vaccine. 2017 03 07; 35(10):1410-1416.
Score: 0.044